Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 1999

View Archived Issues

Sumitomo applies for approval of amrubicin

Soltec enters strategic alliance with Mipharm

Dynal to provide component for Xcyte Therapies' activated T-cell product

NexMed initiates phase II trials of alprostadil cream in U.S.

Two new patents issued to Helix for drug delivery technology

Oxo Chemie reports promising data for immune therapeutic

Licensing opportunity from NIH: glycoprotein hormone superagonists

Allelix/NPS merger approved by stockholders, Canadian court

Vasomax progress updated by Zonagen

Pivotal studies begin for Emitasol

Statins as new approach to the treatment of bone loss diseases

Dexmedetomidine receives FDA marketing approval

Novartis discloses several new compounds for proliferative, inflammatory conditions

FDA is first agency worldwide to approve new fluoroquinolone for marketing

Cytotoxic polyheterocyclic compounds designed at Taiwan research institute

Meiji Seika presents heterocyclic inhibitors of platelet aggregation

New agents for diabetes in development at Otsuka

Pretreatment with complement inhibitor significantly reduces cardiac, brain damage following CPB

Selective, orally active factor Xa inhibitors designed by JT scientists

New FTase inhibitors from Schering-Plough with good cellular activity

MJ-355: a new K(ATP) channel opener with antihypertensive and cardioprotective effects

Scandipharm to become wholly owned subsidiary of Axcan

Acute and chronic effects of two new TZDs on glucose metabolism examined in rats

New agent for treating cocaine dependency in development at RBI

Major regulatory filings made for unique antidiabetic medication

Isis surprised by disappointing results in Crohn's disease study of ISIS-2302

Simultaneous E.U. and U.S. submissions for Combidex, a new MRI contrast agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...